135 related articles for article (PubMed ID: 12352318)
1. Calcium antagonist clevidipine reduces myocardial reperfusion injury by a mechanism related to bradykinin and nitric oxide.
Gourine AV; Pernow J; Poputnikov DM; Sjöquist PO
J Cardiovasc Pharmacol; 2002 Oct; 40(4):564-70. PubMed ID: 12352318
[TBL] [Abstract][Full Text] [Related]
2. Short-acting calcium antagonist clevidipine protects against reperfusion injury via local nitric oxide-related mechanisms in the jeopardised myocardium.
Gourine A; Gonon A; Sjöquist PO; Pernow J
Cardiovasc Res; 2001 Jul; 51(1):100-7. PubMed ID: 11399252
[TBL] [Abstract][Full Text] [Related]
3. Calcium antagonist protects the myocardium from reperfusion injury by interfering with mechanisms directly related to reperfusion: an experimental study with the ultrashort-acting calcium antagonist clevidipine.
Segawa D; Sjöquist PO; Wang QD; Gonon A; Nordlander M; Rydén L
J Cardiovasc Pharmacol; 2000 Sep; 36(3):338-43. PubMed ID: 10975591
[TBL] [Abstract][Full Text] [Related]
4. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part II.
Segawa D; Sjöquist PO; Wang QD; Gonon A; Rydén L
J Cardiovasc Pharmacol; 2002 Sep; 40(3):339-45. PubMed ID: 12198319
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotective effect induced by brief exposure to nitric oxide before myocardial ischemia-reperfusion in vivo.
Gourine AV; Bulhak AA; Gonon AT; Pernow J; Sjöquist PO
Nitric Oxide; 2002 Nov; 7(3):210-6. PubMed ID: 12381417
[TBL] [Abstract][Full Text] [Related]
6. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I.
Wang QD; Segawa D; Ericsson H; Sjöquist PO; Johansson L; Rydén L
J Cardiovasc Pharmacol; 2002 Aug; 40(2):228-34. PubMed ID: 12131552
[TBL] [Abstract][Full Text] [Related]
7. Ischemic preconditioning prevents the impairment of hypoxic coronary vasodilatation caused by ischemia/reperfusion: role of adenosine A1/A3 and bradykinin B2 receptor activation.
Giannella E; Mochmann HC; Levi R
Circ Res; 1997 Sep; 81(3):415-22. PubMed ID: 9285644
[TBL] [Abstract][Full Text] [Related]
8. Failure to demonstrate myocardial protective effects of the ultra short-acting calcium antagonist clevidipine in a closed-chest reperfusion porcine model.
Odenstedt J; Månsson C; Grip L
J Cardiovasc Pharmacol; 2004 Oct; 44(4):407-15. PubMed ID: 15454848
[TBL] [Abstract][Full Text] [Related]
9. Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs.
Shimizu M; Wang QD; Sjöquist PO; Rydén L
J Cardiovasc Pharmacol; 1999 Oct; 34(4):512-7. PubMed ID: 10511125
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotection from ischemia and reperfusion injury by an endothelin A-receptor antagonist in relation to nitric oxide production.
Gonon AT; Gourine AV; Pernow J
J Cardiovasc Pharmacol; 2000 Sep; 36(3):405-12. PubMed ID: 10975600
[TBL] [Abstract][Full Text] [Related]
11. Involvement of nitric oxide in cardioprotective effect of endothelin receptor antagonist during ischemia-reperfusion.
Gourine AV; Gonon AT; Pernow J
Am J Physiol Heart Circ Physiol; 2001 Mar; 280(3):H1105-12. PubMed ID: 11179053
[TBL] [Abstract][Full Text] [Related]
12. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
Koid SS; Ziogas J; Campbell DJ
Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
[TBL] [Abstract][Full Text] [Related]
13. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
Hartman JC
Ann Thorac Surg; 1995 Sep; 60(3):789-92. PubMed ID: 7545893
[TBL] [Abstract][Full Text] [Related]
14. The role of the L-arginine/nitric oxide pathway in myocardial ischaemic and reperfusion injury.
Pernow J; Wang QD
Acta Physiol Scand; 1999 Oct; 167(2):151-9. PubMed ID: 10571551
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide- and prostaglandin-mediated cardioprotection by bradykinin in myocardial ischemia and reperfusion injury.
Veeravalli KK; Akula A; Kota MK
Pol J Pharmacol; 2003; 55(6):1021-9. PubMed ID: 14730097
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control.
Nordlander M; Sjöquist PO; Ericsson H; Rydén L
Cardiovasc Drug Rev; 2004; 22(3):227-50. PubMed ID: 15492770
[TBL] [Abstract][Full Text] [Related]
17. Bradykinin B2 receptor is involved in the late phase of preconditioning in rabbit heart.
Kositprapa C; Ockaili RA; Kukreja RC
J Mol Cell Cardiol; 2001 Jul; 33(7):1355-62. PubMed ID: 11437541
[TBL] [Abstract][Full Text] [Related]
18. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.
Liu YH; Yang XP; Sharov VG; Sigmon DH; Sabbath HN; Carretero OA
Hypertension; 1996 Jan; 27(1):7-13. PubMed ID: 8591891
[TBL] [Abstract][Full Text] [Related]
19. Interaction of nitric oxide and endothelin-1 in ischemia/reperfusion injury of rat heart.
Brunner F
J Mol Cell Cardiol; 1997 Sep; 29(9):2363-74. PubMed ID: 9299360
[TBL] [Abstract][Full Text] [Related]
20. Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin.
Schulz R; Post H; Vahlhaus C; Heusch G
Circulation; 1998 Sep; 98(10):1022-9. PubMed ID: 9737523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
